RXi Pharmaceuticals this week announced that it has started a second double-blind phase I study of its RNAi-based anti-scarring compound RXI-109.

Three cohorts of three patients each will be enrolled to receive three intradermal injections of the drug over two weeks. Dose levels range from 2.5 mg to 7.5 mg per injection, and subjects will receive injections of RXI-109 and its delivery vehicle without the RNAi payload at small incisions on separate areas of their abdomen. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.